AJR 2000; 174:323-331
© American Roentgen Ray Society
Thermal Ablation Therapy for Focal Malignancy
A Unified Approach to Underlying Principles, Techniques, and Diagnostic Imaging Guidance
S. Nahum Goldberg1,
G. Scott Gazelle2 and
Peter R. Mueller2
1
Department of Radiology, Beth Israel Deaconess Medical Center, 330 Brookline
Ave., Boston, MA 02215.
2
Department of Radiology, Massachusetts General Hospital, 32 Fruit St., Boston,
MA 02114.
Received April 26, 1999;
accepted after revision July 19, 1999.
Address correspondence to S. N. Goldberg.
Introduction
Percutaneous imaging-guided ablative therapies using thermal energy sources
such as radiofrequency (RF), microwave, laser, and high-intensity focused
sonography have received much recent attention as minimally invasive
strategies for the treatment of focal malignant diseases
[1,
2]. Possible advantages of
ablative therapies compared with surgical resection include the anticipated
reduction in morbidity and mortality, low cost, suitability for real-time
imaging guidance, and the ability to perform ablative procedures on
outpatients. Promising results have been reported in early clinical trials for
the treatment of hepatocellular carcinoma
[3,
4,
5,
6], hepatic
[7,
8,
9,
10,
11] and cerebral
[12,
13] metastases, renal
[14] and retroperitoneal
[15] tumors, and bony lesions,
including osteoid osteomas
[16,
17].
Many similarities exist among the thermal methods of ablation. However, the
individual techniques used for destruction are often discussed only within the
framework of that particular technology (RF, laser, and so forth), rather than
from a global perspective of looking at thermal therapy as a whole. This
outlook may be shortsighted because many aspects of thermal ablation have been
independently rediscovered. For example, innovations to increase energy
deposition, such as reducing excess heat near the thermal source by internal
cooling, have been shown useful for many techniques including RF, laser,
high-intensity sonography, and microwave
[18,
19,
20,
21]. Additionally, the
biophysical limitations that prevent adequate tumor ablation are innate to
tumor biology and will pose similar problems for all thermal ablation methods.
A key example is the effect of tissue blood flow that limits coagulation in
vivo [22,
23,
24,
25]. Furthermore, issues
related to monitoring of ongoing ablation procedures apply equally to all
these methods, and imaging findings are remarkably similar at follow-up.
Therefore, this perspective proposes a unified framework for discussing the
various aspects of all thermal ablation therapies as they relate to the
treatment of focal malignancies. This framework is based loosely on Pennes'
[26] bioheat equation, which
takes into account the factors that influence tissue heating
(Appendix 1). Briefly, the
extent of coagulation necrosis induced in a given lesion is equal to the
energy deposited, modified by local tissue interactions, minus the heat lost
before inducing thermal damage.
Induction of Coagulation Necrosis
The main aim of thermal tumor ablation therapy is to destroy an entire
tumor by using heat to kill the malignant cells in a minimally invasive
fashion without damaging adjacent vital structures. This therapy often
includes the treatment of a 0.5- to 1-cm margin of apparently healthy tissue
adjacent to the lesion to eliminate microscopic foci of disease and the
uncertainty that often exists regarding the precise location of actual tumor
margins. However, tumor cells can be effectively destroyed by cytotoxic heat
from different sources. As long as adequate heat can be generated throughout
the tumor, our objective of eradicating the tumor will be accomplished.
Therefore, it is necessary to understand how heat interacts with tissue to
induce cell death.
Cellular homeostasis can be maintained with mild elevation of temperature
to approximately 40°C. When temperatures are increased to 42-45°C
(hyperthermia), cells become more susceptible to damage by other agents such
as chemotherapy and radiation
[27,
28]. However, even prolonged
heating at these temperatures will not kill all cells in a given volume
because continued cellular functioning and tumor growth can be observed after
relatively long exposure to these temperatures. When temperatures are
increased to 46°C for 60 min, irreversible cellular damage occurs
[29]. Increasing the
temperature only several degrees to 50-52°C markedly shortens the time
necessary to induce cytotoxicity (4-6 min)
[30]. Between 60° and
100°C, near instantaneous induction of protein coagulation that
irreversibly damages key cytosolic and mitochondrial enzymes and nucleic
acidhistone complexes occurs
[31,
32]. Cells experiencing this
extent of thermal damage most often, but not always, undergo coagulative
necrosis over the course of several days. The term "coagulation
necrosis" has been used to denote irreversible thermal damage to cells,
even if the ultimate manifestations of cell death do not fulfill the strict
histologic criteria of coagulative necrosis. Temperatures greater than
105°C result in tissue boiling, vaporization, and carbonization. These
processes usually retard optimal ablation because of a resultant decrease in
energy transmission [30].
Thus, a key aim for ablative therapies is achieving and maintaining a
50-100°C temperature range throughout the entire target volume.
Sources of Thermal Energy
Multiple energy sources have been used to provide the heat necessary to
induce coagulation necrosis. Electromagnetic energy has been used in the form
of both RF and microwaves [33,
34]. Photocoagulation uses
intense pulses of light produced by a laser as the energy source
[35]. High-intensity focused
sonography uses sound energy to produce heat
[36,
37]. Injection of heated
fluids, including saline, ethanol, and contrast material, has been used to
induce coagulation by direct thermal contact
[38].
For most methods of thermal ablation, energy is applied percutaneously with
needle-shaped applicators. These high doses of energy usually concentrate
around the applicator and require heat conduction through the tissue from this
local thermal reservoir to coagulate deeper tissues. For RF, radio waves
emanate from the noninsulated distal portion of the electrode. Heat is
produced by resistive forces (i.e., ionic agitation) surrounding the electrode
as the radio waves attempt to find their ground, usually a foil pad attached
to the patient's back or thighs. For microwave, needle-shaped electrodes
function as an antenna that concentrates energy around the applicator and
heats the tissue by friction, as polar molecules attempt to align with the
electromagnetic field. For photocoagulation, thin optical fibers that conduct
laser energy are placed through needles positioned in the tumor. These bare
fibers transmit the intense light into the tissue, where the light is
converted to heat. For both microwave and laser, the depth of energy
penetration can be altered by altering the frequency of the energy source.
Percutaneous probes containing multiple small piezoelectric transducers can
deposit sufficient sound energy to heat adjacent tissues. Another potential
application of sonographic energy has been incorporated into extracorporeal
systems of energy delivery. These systems rely on focusing intense energy from
an external sonographic source. Unfortunately, the maximum size for a single
ablative focus has thus far approximated a grain of rice; therefore, complex
imaging-guided systems are necessary to adequately treat larger areas
[36]. However, improvements in
technology may ultimately allow the treatment of larger foci.
Heat-Tissue Interactions
To adequately destroy a tumor, the entire lesion must be subject to
cytotoxic temperatures. However, multiple and often tissue-specific
limitations that prevent heating of the entire tumor volume exist. Most
important, heterogeneity of heat deposition occurs throughout a given lesion
to be treated. For all percutaneous methods, heat deposition is greatest
surrounding the probe, with less heat deposited deeper in the tissues
(Fig. 1). This concentration of
heat is caused by both a rapid falloff of energy from the applicator and poor
heat conduction in the tissues. Additionally, the total quantity of energy
that can be deposited in the tissues is limited by tissue boiling and
vaporization at extreme temperatures (>105°C). When tissue vaporization
occurs, gas is formed. For all methods, this gas serves as an insulator that
prevents heat spread. For RF, gas formation increases tissue impedance that
prevents deposition of the heating current. Energy deposition with a single
applicator (i.e., a monopolar RF electrode or a single laser fiber) produces
coagulation measuring only up to 1.6 cm in diameter
[39,
40,
41].

View larger version (12K):
[in this window]
[in a new window]
[as a PowerPoint slide]
|
Fig. 1. Graph shows tissue temperature profile for thermal ablation with and
without cooling of energy applicator. Temperatures were generated by applying
radiofrequency (RF) for 12 min at maximum tissue temperature of 95°C to in
vivo swine muscle (methodology adapted from
[19]). Internal cooling
permits greater energy deposition in tissues resulting in greater heating at
distance from electrode. This cooling strategy has been used successfully for
multiple energy sources. Solid black line represents conventional (RF), solid
gray line is cooling, and broken line is coagulation threshold.
|
|
Several strategies have been developed to improve tissueenergy
interactions for thermal ablation therapy, with the goal of increasing the
region of induced coagulation to enable the treatment of most clinically
relevant tumors (i.e., those measuring >1-2 cm in diameter)
(Table 1). These strategies can
be classified as those that permit an increase in overall energy (amount and
rate) deposited, those that improve heat conduction within the tissue, and
those that decrease tumor tolerance to heat.
Increasing Energy Deposition
A common method for increasing energy deposition throughout an entire
lesion has been to repeatedly insert multiple RF, laser, and microwave probes
into the tissue to increase the diameter of induced coagulation
[3,
5,
7,
36]. This approach is both
time-consuming and difficult to use in the clinical setting, particularly
because multiple overlapping treatments must be performed in a contiguous
fashion (in all three dimensions) to destroy the entire lesion. Simultaneous
application of energy using arrays can reduce the duration of therapy
[42,
43]. However, the precise
positioning of multiple probes can be technically challenging. The development
of umbrella RF electrodes with multiple hooked arrays has overcome some of
these problems and has enabled the creation of larger zones of coagulation
[3,
9,
44].
Much recent development has centered on strategies that preferentially cool
tissues nearest the probe in an attempt to increase overall energy deposition.
Internally cooled electrodes have been used with RF, microwave, high-intensity
sonography, and laser [18,
19,
20,
21]. For internally cooled
devices, two internal lumens permit the delivery of chilled perfusate to the
tip of the electrode and allow the warmed effluent to be removed to a
collection unit outside the body. This procedure causes a heat-sink effect
that removes heat closest to the electrode
(Fig. 1). Pulsing of energy is
another strategy that has been used with RF and laser to increase the mean
intensity of energy deposited. When pulsing is used, periods of high energy
deposition are rapidly alternated with periods of low energy deposition. If a
proper balance between high and low energy deposition is achieved,
preferential tissue cooling occurs adjacent to the applicator during periods
of minimal energy deposition without significantly decreasing heating deeper
in the tissue. Thus, even greater energy can be applied during periods of high
energy deposition, enabling deeper heat penetration and greater tissue
coagulation [45,
46]. Combination of both
internal cooling and pulsing has been shown as synergistic with even greater
tissue destruction observed than with either method alone
[47].
Improved Tissue Heat Conduction
Improved heat conduction within the tissues by injection of saline and
other compounds has also been proposed
[48,
49,
50]. The heated liquid spreads
thermal energy farther and faster than heat conduction in healthy
"solid" tissue. An additional potential benefit of simultaneous
saline injection is that it increases tissue ionicity, thereby enabling
greater current flow. Similarly, amplification of current shifts with iron
compounds injected or deposited in the tissues before ablation has been used
for RF and microwave [50].
Another primary factor that can alter the extent of coagulation necrosis is
tissue composition because heat conducts through different tissues at various
rates [4,
51]. For example, poor thermal
conduction has been documented for bone compared with muscle
[51]. This fact has been an
advantage in the treatment of hepatocellular carcinomas and vertebral body
lesions. Livraghi et al. [4]
have described the "oven effect" in which cirrhotic tissue
insulates hepatocellular carcinoma nodules and increases temperatures within
the targeted tumor during RF therapy. Dupuy et al.
[51] have shown that cortical
bone also serves as an insulator, enabling treatment of vertebral body lesions
without damaging the spinal cord.
Strategies That Decrease Tumor Tolerance to Heat
Strategies that decrease tumor tolerance to heat have been proposed but are
not yet well studied. Theoretically, previous insult to the tumor cells by
cellular hypoxia caused by vascular occlusion or antiangiogenesis-factor
therapy (i.e., endostatin) or prior tumor cell damage from chemotherapy or
radiation could be used to increase tumor sensitivity to heat. Synergy between
chemotherapeutic agents and hyperthermic temperatures (42-45°C) has
already been established [27,
28].
Sources of Heat Loss
Biophysical aspects of tumorheat interaction must be taken into
account when performing thermal ablation therapies. The extent of induced
coagulation compared with the reproducible results obtainable in ex vivo
tissue is more limited and variable in vivo and in tumors. Substantial
evidence suggests that perfusion-mediated tissue cooling (vascular flow)
reduces the extent of coagulation necrosis produced by thermal ablation
[22,
23,
24,
25]. Decreased volume of
coagulation has been observed when comparing in vivo liver with ex vivo and
nonperfused liver, with coagulation necrosis in vivo often shaped by hepatic
vasculature. Furthermore, experiments altering hepatic perfusion by vascular
occlusion during RF and laser ablation of healthy liver and tumors strongly
support the contention that perfusion-mediated tissue cooling is largely
responsible for reduction in observed coagulation
[22,
23,
24,
25]. A close correlation
between the diameter of RF-induced coagulation and pharmacologically modulated
blood flow in the healthy liver has also been shown
[23]. Thus, with in vivo
tissues a heat-sink effect prevents achieving the cytotoxic temperature
necessary to induce coagulation (50-60°C) in highly vascular regions of a
tumor (i.e., the peripheral tumorparenchyma interface).
On the basis of these observations, several strategies for reducing blood
flow during ablation therapy were proposed. Total portal inflow occlusion
(Pringle's maneuver) has been used but requires open laparotomy
[22]. Angiographic balloon
occlusion can be used but may not prove adequate for intrahepatic ablation
because of the dual hepatic blood supply with redirection of compensated flow
[22]. Embolotherapy before
ablation with particulates that occlude sinusoids such as a gelatin sponge
(Gelfoam; Upjohn, Kalamazoo, MI) or iodized oil (Lipiodol;
Roissey-Charles-de-Gaullle, France) may overcome this limitation
[52]. Pharmacologic modulation
of blood flow and antiangiogenesis therapy are theoretically possible but
should currently be considered experimental.
Diagnostic Imaging for Thermal Ablation Therapy
Diagnostic imaging applications can accomplish three distinct tasks for
thermal ablation procedures. These tasks include targeting of the lesion to be
treated (i.e., ensuring optimal positioning of the energy applicator during
ablation), guidance for energy deposition for the duration of the treatment
plan, and assessment of results at follow-up. The imaging appearances for
laser, microwave, and RF are remarkably similar for any given organ and degree
of tissue heating. Needlelike applicators will all look approximately the same
for any given technique, and coagulated (or heated) tissues should
theoretically appear identical for a given extent of coagulation, regardless
of how it is induced.
Diagnostic Imaging for Lesion Targeting
Multiple imaging techniques (sonography, CT, and MR imaging) can be used to
guide the percutaneous placement of thermal energy applicators into the
selected target [1,
2]. Because in most cases
adequate lesion conspicuity and visualization of the applicator can be
achieved with any of these methods, the choice of imaging technique is often
dictated by personal preference or research interests. Most imaging-guided
thermal ablation procedures have thus far been performed with sonography (Fig.
2A,
2B,
2C). Benefits claimed for
sonography include the real-time visualization of applicator placement,
portability of the technology, nearly universal availability, low cost, and
ability to target and guide ablation therapy with intracavitary endoluminal
transducers (i.e., for transrectal or transgastric energy application to the
prostate and abdominal organs). Limitations of sonography include occasional
poor lesion visualization as a result of a lack of innate tissue conspicuity
or overlying bone- or gas-containing structures. MR imaging generally provides
greatest tumor-to-tissue conspicuity and the ability to use multiplanar
guidance. However, this technology is relatively expensive, requires
specialized ablation equipment that is compatible with a high magnetic field,
and is the least available for general clinical use. CT and, more recently,
real-time CT fluoroscopy have also been used to ensure adequate positioning of
the energy applicator. Though CT fluoroscopy has not been extensively
evaluated, it is fair to say that CT falls between sonography and MR imaging
with respect to cost, tissue contrast, and complexity. In our clinical
practice, we use a combined approach of CT fluoroscopy and sonography at the
same setting to document optimal RF electrode positioning
(Fig. 3B).

View larger version (145K):
[in this window]
[in a new window]
[as a PowerPoint slide]
|
Fig. 2A. 63-year-old man with 2.4-cm colorectal metastasis undergoing
sonographically guided radiofrequency (RF) ablation. Gray-scale sonogram shows
metastasis (large arrows) before RF treatment. Electrode (small
arrows) has been percutaneously inserted into tumor.
|
|

View larger version (144K):
[in this window]
[in a new window]
[as a PowerPoint slide]
|
Fig. 2B. 63-year-old man with 2.4-cm colorectal metastasis undergoing
sonographically guided radiofrequency (RF) ablation. Sonogram obtained during
RF application shows progressive echogenicity surrounding tip of electrode
(arrows).
|
|

View larger version (149K):
[in this window]
[in a new window]
[as a PowerPoint slide]
|
Fig. 2C. 63-year-old man with 2.4-cm colorectal metastasis undergoing
sonographically guided radiofrequency (RF) ablation. Sonogram obtained 15 min
after RF ablation shows no echogenicity within tumor (arrow).
|
|

View larger version (152K):
[in this window]
[in a new window]
[as a PowerPoint slide]
|
Fig. 3B. 58-year-old man with cirrhosis and 4-cm hepatoma treated with
radiofrequency (RF) ablation using CT fluoroscopic guidance. CT fluoroscopy
image obtained during electrode insertion (arrows) shows electrode
centered in tumor.
|
|
Diagnostic Imaging to Guide Therapy
To prevent under- or overtreatment of a lesion, it is essential to have
accurate and reliable methods for determining the adequacy of therapy. Thus,
significant investigation into the development of imaging strategies that
enable rapid assessment of the extent of tissue destruction induced by thermal
ablation is being conducted. Despite initial enthusiasm, gray-scale
sonographic findings observed during the thermal ablation procedure are not
sufficiently accurate in predicting the extent of coagulation
[7,
8,
53]. The progressively
increasing hyperechogenic focus often seen surrounding the distal portion of
the applicator during the application of energy represents microbubbles of gas
that form in the heated tissue and does not represent tissue coagulation
[54]
(Fig. 2B). This hyperechogenic
region can be variable in size, may be quite irregular in shape and contour,
and often shows complete resolution within 1 hr of ablation
(Fig. 2C). Additionally, this
intense echogenicity can often obscure the energy applicator and tumor while
increasing the difficulty of repositioning for further treatment.
Conventional color-flow and power Doppler sonography have similarly not
been found useful in assessing the extent of induced coagulation
[7,
8]. However, in one study
contrast-enhanced color Doppler sonography with a synthetic microbubble
sonographic contrast agent was able to achieve 92% accuracy in predicting the
extent of coagulation in VX2 rabbit tumors immediately after RF ablation
[55]. Additionally,
sonographic contrast material has been used to direct a second energy
application to residual enhancing (and presumably viable) foci within the
treatment zone [56].
For solid organs such as the liver, unenhanced CT scans obtained
immediately after ablation often reveal increased density at the center of the
treatment zone, most often surrounded by a region of hypoattenuation
[3,
4,
5,
6,
7,
8,
9,
10,
11,
12,
13,
53,
57,
58]. With the exception of
encapsulated lesions such as those of hepatocellular carcinoma, the margins of
this outer hypodense zone are often too diffuse to be of sufficient
sensitivity to assess therapy. However, contrast-enhanced CT is useful in
discriminating between ablated and residual viable tumor immediately after
thermal ablation because it shows regions of hypoattenuation devoid of
characteristic tumorous or parenchymal enhancement in treated portions of the
tumor. For intrahepatic metastases, the differentiation of coagulation
necrosis from hypoattenuating tumor is usually easiest on images in the
equilibrium phase of contrast enhancement (5-10 min after iodinated contrast
administration). At this phase, persistent hypoattenuation is seen in
coagulated tissues but not in viable tumor
[31]. Hepatic arterial phase
images are most useful for early-enhancing hepatocellular carcinomas (Fig.
3A,
3B,
3C,
3D). Imaging during the hepatic
arterial phase can also show a thin rim of contrast material corresponding on
histopathology to an early inflammatory reaction to the thermal damage
(Fig. 3C). This inflammatory
rim can be seen immediately after ablation and often regresses during the
first month after treatment.

View larger version (175K):
[in this window]
[in a new window]
[as a PowerPoint slide]
|
Fig. 3A. 58-year-old man with cirrhosis and 4-cm hepatoma treated with
radiofrequency (RF) ablation using CT fluoroscopic guidance. Arterial phase CT
scan shows hypervascular hepatoma (arrow) before RF treatment.
|
|

View larger version (155K):
[in this window]
[in a new window]
[as a PowerPoint slide]
|
Fig. 3C. 58-year-old man with cirrhosis and 4-cm hepatoma treated with
radiofrequency (RF) ablation using CT fluoroscopic guidance. Contrast-enhanced
CT scan obtained 15 min after procedure shows that entire tumor is devoid of
parenchymal enhancement. Enhancing hyperdense rim surrounds treatment zone
(arrow).
|
|

View larger version (184K):
[in this window]
[in a new window]
[as a PowerPoint slide]
|
Fig. 3D. 58-year-old man with cirrhosis and 4-cm hepatoma treated with
radiofrequency (RF) ablation using CT fluoroscopic guidance. Contrast-enhanced
CT scan at 6-month follow-up shows no evidence of enhancement or hypervascular
rim. These findings suggest, but are not definitive of, adequate
treatment.
|
|
MR images characteristically reveal altered signal on both T1- and
T2-weighted images [53,
57,
59] (Fig.
4A,
4B,
4C,
4D). Treated areas are devoid
of gadolinium enhancement. Several studies have documented the particular
usefulness of decreased signal on T2-weighted images as a marker for induced
coagulation [59,
60].
Radiologicpathologic correlation in both experimental and clinical
studies has shown that CT and MR imaging findings predict the region of
coagulation to within 2-3 mm
[31].

View larger version (149K):
[in this window]
[in a new window]
[as a PowerPoint slide]
|
Fig. 4A. 74-year-old-man with biopsy-proven colorectal metastasis 3 weeks
after radiofrequency ablation of one lesion. T1-weighted image shows
heterogeneous but concentric signal throughout treatment zone (solid
arrow). Second untreated lesion shows traditional signal characteristics
(open arrow).
|
|

View larger version (174K):
[in this window]
[in a new window]
[as a PowerPoint slide]
|
Fig. 4B. 74-year-old-man with biopsy-proven colorectal metastasis 3 weeks
after radiofrequency ablation of one lesion. T2-weighted image shows similar
concentric pattern of altered signal in treatment zone (solid arrow).
Open arrow indicates untreated lesion.
|
|

View larger version (163K):
[in this window]
[in a new window]
[as a PowerPoint slide]
|
Fig. 4C. 74-year-old-man with biopsy-proven colorectal metastasis 3 weeks
after radiofrequency ablation of one lesion. Gadolinium-enhanced T1-weighted
image shows no evidence of central enhancement. Thin peripheral rim of
contrast enhancement is identified (solid arrow) and corresponds to
early inflammatory response to treatment. Open arrow indicates untreated
lesion.
|
|

View larger version (138K):
[in this window]
[in a new window]
[as a PowerPoint slide]
|
Fig. 5A. 84-year-old man with 3.5-cm biopsy-proven renal cell carcinoma
undergoing radiofrequency ablation. Contrast-enhanced CT scan before therapy
shows marked enhancement of solid exophytic tumor (solid arrow).
Incidental simple cyst abuts tumor (open arrow).
|
|
One key advantage of MR imaging over other diagnostic imaging techniques is
its ability to aid in determining the extent of coagulation during energy
application. Heat-sensitive sequences have been constructed and permit
tailoring of energy deposition
[61,
62,
63]. Such a strategy is most
useful in allowing the operator to limit energy deposition when heating
adjacent to a critical structure (i.e., nerves) reaches cytotoxic
temperatures. Pulsing switches were developed to overcome interference of RF
and microwave usage during the acquisition of MR-RF encoded data
[64].
Long-Term Imaging Follow-Up
Although initial imaging can serve as a good indication of the adequacy of
therapy, the resolution and accuracy of current imaging techniques preclude
identification of residual microscopic foci of malignancy, particularly at the
periphery of a treated lesion (where blood flow is greatest). These viable
tumor foci will inevitable continue to grow and, if untreated, will result in
failed therapy. Additionally, considering issues of sampling error and the
possible difficulty in differentiating between adequately treated and viable
tumors with histopathologic techniques alone, we have not found the use of
needle biopsy helpful. Thus, longterm imaging follow-up is necessary to find
untreated regions of the tumor or to document complete treatment of a given
focal malignancy.
Long-term follow-up of thermal ablation with sonography has limited value
[7,
8]. Obscuration of the
characteristic peritumoral halo observed before treatment is often seen, and
the variability of gray-scale sonographic changes precludes accurate
assessment of induced coagulation. Sonographic microbubble blood pool agents
such as SH 508 A (Levovist; Schering, Berlin, Germany) may be helpful in
differentiating treated tumor from the avascular coagulation at 6 months of
follow-up [65].
Contrast-enhanced CT has been the mainstay of long-term imaging follow-up
(Figs. 3A,
3B,
3C,
3D and
5A,
5B). Coagulated nonenhancing
regions increase in conspicuity and develop sharper margins by 2 weeks after
ablation [31,
53]. Imaging at 6-12 months
can show marked regression of the lesion and the region of induced coagulation
necrosis. Most commonly, the nonenhancing treatment focus shrinks less than
20% in volume. A peripheral rim that densely enhances on delayed contrast
images often surrounds the region of coagulation. This finding should not be
misconstrued as residual tumor, for experimental and clinical studies have
shown this rim to represent an inflammatory reaction to the thermally damaged
cells [53,
66]. A bulky irregular rim at
the edge of a treatment site is the most common appearance of an incompletely
treated lesion (Fig. 6).

View larger version (134K):
[in this window]
[in a new window]
[as a PowerPoint slide]
|
Fig. 5B. 84-year-old man with 3.5-cm biopsy-proven renal cell carcinoma
undergoing radiofrequency ablation. Contrast-enhanced CT scan 6 months after
ablation shows no contrast enhancement compared with baseline unenhanced study
(arrow). Simple cyst is unchanged.
|
|

View larger version (150K):
[in this window]
[in a new window]
[as a PowerPoint slide]
|
Fig. 6. 73-year-old woman with 6.5-cm metastasis from squamous cell
carcinoma with inadequate treatment of tumor margins after radiofrequency (RF)
ablation. CT image obtained 3 months after ablation shows enhancing bulky
peripheral tumor growth (arrows) surrounding nonenhancing treated
center (A). Five centimeters of coagulation was obtained with single 12-min RF
application using clustered electrode approach.
|
|
When using MR imaging for long-term follow-up (>3 months), we have
relied primarily on the presence or absence of gadolinium enhancement in the
treated region [8,
53]. In comparison with MR
images obtained within 3 days of ablation, we have observed heterogeneous
alteration on unenhanced T1- and T2-weighted images
(4A,
4B,
4C,
4D). This changing variability
in signal intensity throughout the ablated region is most likely caused by an
uneven evolution of the necrotic area and the host response to thermal damage.
Hence, these images have been thus far too variable to be relied on as
adequate proof of tumor destruction. The multiplicity of potential imaging
sequences and parameters used for MR imaging has only further compounded this
problem. Further research may ultimately lead to greater insight into the
biologic mechanisms that account for such signal heterogeneity. For
gadolinium-enhanced images, it is also common to detect a thin rim of
enhancement after treatment. As for CT scans, only when this rim appears bulky
is this finding to be interpreted as representing an untreated tumor.
Nuclear medicine has been used in a limited number of patients after
ablation therapy. In one study, positron emission tomography scanning with a
radioactive glucose analog (18F-fluorodeoxyglucose) was used to
detect active foci of residual tumor after percutaneous ethanol instillation
in intrahepatic metastases
[67].
Our current imaging strategy after thermal ablation includes an initial
contrast-enhanced CT or MR study on the day of treatment to determine whether
the patient has residual gross viable disease that requires immediate
retreatment. Follow-up imaging is then performed at 1 and 3 months, and every
3-4 months thereafter. These scans are helpful in documenting the presence or
absence of residual tumor that often may be amenable to additional thermal
ablation treatment. If no evidence of peripheral tumor regrowth is seen by
6-12 months, adequate treatment can be inferred.
Trends for Thermal Ablation Therapy
The ultimate goal of tumor therapy is complete eradication of all malignant
cells. Given the high likelihood of incomplete treatment by heatbased
techniques alone, the case for combining thermal ablation with other therapies
such as chemotherapy or chemoembolization cannot be overstated. A similar
multidisciplinary approach including surgery, radiation, and chemotherapy is
used for the treatment of most solid tumors. Given the variety of tumor types
and organ sites to be treated, we think that it is overly optimistic to
believe that all tumors can be destroyed with only one technique. Combination
therapy is a key avenue of current ablation research.
Presently, many thermal ablation devices are being studied with multiple
commercial devices now becoming available. Given the rapid pace of evolution
in the state of the art for ablation technologies, we cannot confidently
predict which method (if any) will prove dominant for any given clinical
application. Competitive technologies must be able to ablate the desired
volume of tissue in a reproducible and predictable fashion. However, other
factors, including ease of clinical use and cost, will play a role in
determining which of these technologies will receive the greatest
attention.
Conclusion
Percutaneous imaging-guided thermal ablation therapy is an exciting and
emerging arena that has thus far provided optimistic results for the minimally
invasive treatment of selected focal neoplasms. Key questions that need to be
addressed include definition of optimal methods and techniques for heating
tumors, identification of optimal diagnostic imaging strategies to guide
therapy and clinical follow-up, and determination of clinical impact for a
given tumor or organ. For tumor heating, one must consider which technical
innovations will enable efficient and efficacious energy deposition and which
biologic factors can be successfully modulated to increase heat deposition and
retention in the treated tumor. The answers to these questions will require
substantial research that is ongoing at multiple tertiary centers. Hopefully,
this work and well-conducted randomized multicenter trials will determine the
proper role for this promising new paradigm of thermal ablation and the role
these technologies will have throughout the general radiology community.
References
-
Goldberg SN, Livraghi T, Solbiati L, Gazelle GS. In situ ablation
of focal hepatic neoplasms. In: Gazelle GS, Saini S, Mueller PR, eds. Hepatobiliary and pancreatic radiology: imaging and
intervention
. New York: Thieme,
1997:470-502
-
De Sanctis JT, Goldberg SN, Mueller PR. Percutaneous treatment of
hepatic neoplasms: a review of current techniques. Cardiovasc Intervent
Radiol
1998;21:273-296[Medline]
-
Rossi S, Buscarini E, Garbagnati F, et al. Percutaneous treatment
of small hepatic tumors by an expandable RF needle electrode. AJR
1998;170:1015-1022[Abstract/Free Full Text]
-
Livraghi T, Goldberg SN, Meloni F, Solbiati L, Gazelle GS.
Hepatocellular carcinoma: comparison of efficacy between percutaneous ethanol
instillation and radiofrequency. Radiology
1999;210:655-663[Abstract/Free Full Text]
-
Seki T, Wakabayashi M, Nakagawa T, et al. Ultrasonically guided
percutaneous microwave coagulation therapy for small hepatocellular carcinoma. Cancer
1994;74:817-825[Medline]
-
Murakami R, Yoshimatsu S, Yamashita Y, Matsukawa T, Takahashi M,
Sagara K. Treatment of hepatocellular carcinoma: value of percutaneous
microwave coagulation. AJR
1995;164:1159-1164[Abstract/Free Full Text]
-
Solbiati L, Ierace T, Goldberg SN, et al. Percutaneous US-guided
radio-frequency tissue ablation of liver metastases: treatment and follow-up
in 16 patients. Radiology
1997;202:195-203[Abstract/Free Full Text]
-
Solbiati L, Goldberg SN, Ierace T, Livraghi T, Sironi S, Gazelle
GS. Hepatic metastases: percutaneous radio-frequency ablation with cooled-tip
electrodes. Radiology
1997;205:367-374[Abstract/Free Full Text]
-
Siperstein AE, Rogers SJ, Hansen PD, Gitomirsky A. Laparoscopic
thermal ablation of hepatic neuroendocrine tumor metastases. Surgery
1997;122:1147-1155[Medline]
-
Vogl TJ, Muller PK, Hammerstingl R, et al. Malignant liver tumors
treated with MR imaging-guided laser-induced thermotherapy: technique and
prospective results. Radiology
1995;196:257-265[Abstract/Free Full Text]
-
Dodd GD, Halff GA, Rhim H, Chintapalli KN, Chopra S, Karahan OI.
Radio-frequency thermal ablation of liver tumors (abstr). Radiology
1998;209(P):449[Abstract/Free Full Text]
-
Anzai Y, Lufkin R, DeSalles A, Hamilton DR, Farahani K, Black KL.
Preliminary experience with MR-guided thermal ablation of brain tumors. AJNR
1995;16:39-48[Abstract]
-
McGovern FJ, Wood BJ, Goldberg SN, Mueller PR. Radiofrequency
ablation of renal cell carcinoma via image guided needle electrodes. J
Urol
1999;161:599-600[Medline]
-
Zlotta AR, Wildschutz T, Raviv G, et al. Radiofrequency
interstitial tumor ablation (RITA) is a possible new modality for treatment of
renal cancer: ex vivo and in vivo experience. J Endourol
1997;11:251-258[Medline]
-
Lewin JS, Connell CF, Duerk JL, et al. Interactive MRI-guided
radiofrequency interstitial thermal ablation of abdominal tumors: clinical
trial for evaluation of safety and feasibility. J Magn Reson
Imaging
1998;8:40-47[Medline]
-
Rosenthal DI, Hornicek FJ, Wolfe MW, Jennings LC, Gephart MC,
Mankin HJ. Changes in the management of osteoid osteoma. J Bone Joint
Surg Am
1998;80-A:815-821[Abstract/Free Full Text]
-
Dupuy DE, Safran H, Mayo-Smith WW, Goldberg SN. Radiofrequency
ablation of painful osseous metastases (abstr). Radiology
1998;209(P):389
-
Goldberg SN, Gazelle GS, Solbiati L, Rittman WJ, Mueller PR.
Radiofrequency tissue ablation: increased lesion diameter with a perfusion
electrode. Acad Radiol
1996;3:636-644[Medline]
-
Yeh MM, Trembly BS, Douple EB, et al. Theoretical and experimental
analysis of air cooling for intracavitary microwave hyperthermia applicators. IEEE Trans Biomed Eng
1994;41:874-882[Medline]
-
Vogl TJ, Mack MG, Roggan A, et al. Internally cooled power laser
for MR-guided interstitial laser-induced thermotherapy of liver lesions:
initial clinical results. Radiology
1998;209:381-385[Abstract/Free Full Text]
-
Deardorff DL, Diederich CJ, Nau WH. Ultrasound applicators with
internal cooling for interstitial thermal therapy. In: Ryan TP, Wong TZ, eds. Thermal treatment of tissue with image guidance: proceedings
,
vol. 3594. Bellingham, WA: Society of Photo-Optical
Instumentation Engineers,
1999:36-46
-
Goldberg SN, Hahn PF, Tanabe KK, et al. Percutaneous radiofrequency
tissue ablation: does perfusion-mediated tissue cooling limit coagulation
necrosis? J Vasc Interv Radiol
1998;9:101-111[Medline]
-
Goldberg SN, Hahn PF, Halpern E, Fogle R, Gazelle GS.
Radiofrequency tissue ablation: effect of pharmacologic modulation of blood
flow on coagulation diameter. Radiology
1998;209:761-769[Abstract/Free Full Text]
-
Patterson EJ, Scudamore CH, Owen DA, Nagy AG, Buczkowski AK.
Radiofrequency ablation of porcine liver in vivo: effects of blood flow and
treatment time on lesion size. Ann Surg
1998;227:559-565[Medline]
-
Heisterkamp J, van Hillegersberg R, Mulder PG, Sinofsky EL,
Ijzermans JN. Importance of eliminating portal flow to produce large
intrahepatic lesions with interstitial laser coagulation. Br J
Surg
1997;84:1245-1248[Medline]
-
Pennes HH. Analysis of tissue and arterial blood temperatures in
the resting human forearm. J Appl Physiol
1948;1:93-122[Free Full Text]
-
Seegenschmiedt MH, Brady LW, Sauer R. Interstitial
thermoradiotherapy: review on technical and clinical aspects. Am J Clin
Oncol
1990;13:352-363[Medline]
-
Overgaard J. Hyperthermia as an adjuvant to radiotherapy: review of
the randomized multicenter studies of the European Society for Hyperthermic
Oncology. Strahlenther Onkol
1987;163:453-457[Medline]
-
Larson TR, Bostwick DG, Corica A. Temperature-correlated
histopathologic changes following microwave thermoablation of obstructive
tissue in patients with benign prostatic hyperplasia. Urology
1996;47:463-469[Medline]
-
Goldberg SN, Gazelle GS, Halpern EF, Rittman WJ, Mueller PR,
Rosenthal DI. Radiofrequency tissue ablation: importance of local temperature
along the electrode tip exposure in determining lesion shape and size. Acad Radiol
1996;3:212-218[Medline]
-
Goldberg SN, Solbiati L, Gazelle GS, Tanabe KK, Compton CC, Mueller
PR. Treatment of intrahepatic malignancy with radio-frequency ablation:
radiologic-pathologic correlation in 16 patients (abstr). AJR
1997;168[American Roentgen Ray
Society 97th Annual Meeting Program Book
suppl]:121
-
Thomsen S. Pathologic analysis of photothermal and photomechanical
effects of laser-tissue interactions. Photochem Photobiol
1991;53:825-835[Medline]
-
Cosman ER, Nashold BS, Ovelman-Levitt J. Theoretical aspects of
radiofrequency lesions in the dorsal root entry zone. Neurosurgery
1984;15:945-950[Medline]
-
Trembley BS, Ryan TP, Strohbehn JW. Interstitial hyperthermia:
physics, biology and clinical aspects. In: Urano M, Douple E, eds. Physics of microwave hyperthermia in hyperthermia and oncology
,
vol 3. Utrecht, the Netherlands: Verlag Springer,
1992:11-98
-
Amin Z, Brown SG, Lees WR. Liver tumor ablation by interstitial
laser photocoagulation: review of experimental and clinical studies. Semin Intervent Radiol
1993;10:88-100
-
Cline HE, Hynynen K, Watkins RD, et al. Focused US system for MR
imaging-guided tumor ablation. Radiology
1995;194:3:731-737
-
Diederich CJ, Nau WH, Deardorff DL, et al. Prostate thermal therapy
with interstitial and transurethral ultrasound applicators: a feasibility
study. In: Ryan TP, ed. Surgical applications of energy:
proceedings, vol. 3294. Bellingham, WA: Society
of Photo-Optical Instrumentation Engineers,
1998:2-13
-
Honda N, Guo Q, Uchida H, Ohishi H, Hiasa Y. Percutaneous hot
saline injection therapy for hepatic tumors: an alternative to percutaneous
ethanol injection therapy. Radiology
1994;190:53-57[Abstract/Free Full Text]
-
McGahan JP, Brock JN, Tessluk H, Gu WZ, Schneider P, Browning PD.
Hepatic ablation with use of radio-frequency electrocautery in the animal
model. J Vasc Interv Radiol
1992;3:291-297[Medline]
-
Goldberg SN, Gazelle GS, Dawson SL, Rittman WJ, Mueller PR,
Rosenthal DI. Tissue ablation with radiofrequency: effect of probe size,
gauge, duration, and temperature on lesion volume. Acad Radiol
1995;2:399-404[Medline]
-
Nolsoe CP, Torp-Pedersen S, Burcharth F, et al. Interstitial
hyperthermia of colorectal liver metastases with a US-guided ND-YAG laser with
a diffuser tip: a pilot clinical study. Radiology
1993;187:333-337[Abstract/Free Full Text]
-
Goldberg SN, Gazelle GS, Dawson SL, Mueller PR, Rittman WJ,
Rosenthal DI. Radiofrequency tissue ablation using multiprobe arrays: greater
tissue destruction than multiple probes operating alone. Acad
Radiol
1995;2:670-674[Medline]
-
Amin Z, Donald JJ, Masters A, et al. Hepatic metastases:
interstitial laser photocoagulation with real-time US monitoring and dynamic
CT evaluation of treatment. Radiology
1993;187:339-347[Abstract/Free Full Text]
-
Leveen RF. Laser hyperthermia and radiofrequency ablation of
hepatic lesions. Semin Intervent Radiol
1997;14:313-324
-
Goldberg SN, Gazelle GS, Solbiati L, Mullin K, Rittman WJ, Mueller
PR. Large volume radiofrequency tissue ablation: increased coagulation with
pulsed technique (abstr). Radiology
1997;205(P):258
-
Nishioka NS, Domankevitz Y, Flotte TJ, Anderson RR. Ablation of
rabbit liver, stomach and colon with a pulsed holmium laser. Gastroenterology
1989;96:831-837[Medline]
-
Goldberg SN, Stein M, Gazelle GS, Kruskal J, Clouse ME.
Percutaneous RF tissue ablation: optimization of pulsed-radio-frequency
technique to increase coagulation necrosis. J Vasc Interv
Radiol
1999;10:907-916[Medline]
-
Livraghi T, Goldberg SN, Monti F, et al. Saline-enhanced
radio-frequency tissue ablation in the treatment of liver metastases. Radiology
1997;202:205-210[Abstract/Free Full Text]
-
Hoey MF, Paul S, Nakib NA. Saline spread and conductivity of the
liquid electrode in the liver for radiofrequency energy application (abstr). Radiology
1998;209(P):448
-
Merkle E, Goldberg SN, Lewin JS. Effect of supraparamagnetic MR
contrast agents on radio-frequency ablation. Radiology
1999;212:459-466[Abstract/Free Full Text]
-
Dupuy DE, Goldberg SN, Gazelle GS, Rosenthal DI. Cooled-tip
radio-frequency ablation in the vertebral body: temperature distribution in
the spinal canal (abstr). Radiology
1997;807(P):330
-
Murakami T, Shibata T, Ishida T, et al. Percutaneous microwave
hepatic tumor coagulation with segmental hepatic blood flow occlusion in seven
patients. AJR
1999;172:637-640[Abstract/Free Full Text]
-
Goldberg SN, Gazelle GS, Solbiati L, et al. Percutaneous
radiofrequency liver tumor ablation. AJR
1998;170:1023-1028[Free Full Text]
-
Malone DE, Lesiuk L, Brady AP, Wyman DR, Wilson BC. Hepatic
interstitial laser photocoagulation: demonstration and possible clinical
importance of intravascular gas. Radiology
1994;193:233-237[Abstract/Free Full Text]
-
Goldberg SN, Walovitch R, Halpern EF, Gazelle GS. Immediate
detection of radiofrequency induced coagulation necrosis using an ultrasound
contrast agent. Radiology
1999;213:438-444[Abstract/Free Full Text]
-
Bartolozzi C, Lencioni R, Ricci P, Paolicchi A, Rossi P,
Passariello R. Hepatocellular carcinoma treatment with percutaneous ethanol
injection: evaluation with contrast-enhanced color Doppler US. Radiology
1998;209:387-393[Abstract/Free Full Text]
-
Hyodoh H, Hyodoh K, Takahashi K, et al. Microwave coagulation
therapy on hepatomas: CT and MR appearance after therapy. J Magn Reson
Imaging
1998;8:451-458[Medline]
-
Mitsuzaki K, Yamashita Y, Nishiharu T, et al. CT appearance of
hepatic tumors after microwave coagulation therapy. AJR
1998;171:1397-1403[Abstract/Free Full Text]
-
Boaz TL, Lewin JS, Chung YC, Duerk JL. MR monitoring of MR-guided
radiofrequency thermal ablation of normal liver in an animal model. J
Magn Reson Imaging
1998;8:64-69[Medline]
-
Mueller-Lisse UG, Thoma M, Faber S, et al. Coagulative interstitial
laser-induced thermotherapy of benign prostatic hyperplasia: online imaging
with a T2-weighted fast spin-echo MR sequenceexperience in six
patients. Radiology
1999;210:373-379[Abstract/Free Full Text]
-
Steiner P, Botnar R, Goldberg SN, Gazelle GS, Debatin JF.
Monitoring of radio-frequency tissue ablation in an interventional MR
environment: preliminary ex vivo and in vivo results. Invest
Radiol
1997;32:671-678[Medline]
-
Busse H, Rassek M, Grust A, Kahn T, Schwarzmaier HJ. Improved
qualitative MR thermometry using a 1.5 T scanner to monitor cooled applicator
systems during laser-induced interstitial thermotherapy (LITT). In: Ryan TP,
Wong TZ, eds. Thermal treatment of tissue with image guidance:
proceedings, vol. 3594. Bellingham, WA: Society
of Photo-Optical Instrumentation Engineers,
1999:96-203
-
Samulski TV, Jones E, Henke F, Buffalo C, Scott T, MacFall JM.
Magnetic resonance image guided thermal therapy with a radiofrequency phased
array. In: Ryan TP, Wong TZ, eds. Thermal treatment of tissue with
image guidance: proceedings, vol. 3594.
Bellingham, WA: Society of Photo-Optical Instrumentation Engineers,
1999:124-128
-
Zhang, Q, Chung, YC, Lewin, JS, Duerk, JL. A method for
simultaneous radiofrequency ablation and MRI. J Magn Reson
Imaging
1998;8:110-114[Medline]
-
Solbiati L, Goldberg SN, Ierace T, DellaNoce M, Livraghi T, Gazelle
GS. Microbubble ultrasound contrast agents: a useful adjunct for
radiofrequency tumor ablation. Radiology
1999;211:643-649[Abstract/Free Full Text]
-
Goldberg SN, Mallery S, Brugge W, Gazelle GS. Endoscopic
ultrasound: guided radiofrequency (RF) ablation in pancreasresults in
porcine model. Gastrointest Endosc
1999;50:392-401[Medline]
-
Dawson SL, Mueller PR, Lee MJ, Boland GW, Goldberg MA, Fischman AJ.
Value of PET imaging in evaluation of percutaneous ablation of malignant
hepatic neoplasms (abstr). Radiology
1994;193(P)582:221

CiteULike
Complore
Connotea
Del.icio.us
Digg
Reddit
Technorati What's this?
This article has been cited by other articles:

|
 |

|
 |
 
M.-h. Park, H. Rhim, Y.-s. Kim, D. Choi, H. K. Lim, and W. J. Lee
Spectrum of CT Findings after Radiofrequency Ablation of Hepatic Tumors
RadioGraphics,
March 1, 2008;
28(2):
379 - 390.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
A. Hakime, A. Hines-Peralta, H. Peddi, M. B. Atkins, V. P. Sukhatme, S. Signoretti, M. Regan, and S. N. Goldberg
Combination of Radiofrequency Ablation with Antiangiogenic Therapy for Tumor Ablation Efficacy: Study in Mice
Radiology,
August 1, 2007;
244(2):
464 - 470.
[Abstract]
[Full Text]
[PDF]
|
 |
|